CN106659725A - 用于治疗细菌感染的稠合螺环杂芳族化合物 - Google Patents

用于治疗细菌感染的稠合螺环杂芳族化合物 Download PDF

Info

Publication number
CN106659725A
CN106659725A CN201580027395.7A CN201580027395A CN106659725A CN 106659725 A CN106659725 A CN 106659725A CN 201580027395 A CN201580027395 A CN 201580027395A CN 106659725 A CN106659725 A CN 106659725A
Authority
CN
China
Prior art keywords
mycoplasma
ureaplasma
fluoro
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580027395.7A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·休班德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN106659725A publication Critical patent/CN106659725A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580027395.7A 2014-05-29 2015-05-27 用于治疗细菌感染的稠合螺环杂芳族化合物 Pending CN106659725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
US62/004,246 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
CN106659725A true CN106659725A (zh) 2017-05-10

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027395.7A Pending CN106659725A (zh) 2014-05-29 2015-05-27 用于治疗细菌感染的稠合螺环杂芳族化合物

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018233663A1 (zh) * 2017-06-22 2018-12-27 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031195A1 (en) * 2002-10-07 2004-04-15 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
CN102245605A (zh) * 2008-10-14 2011-11-16 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031195A1 (en) * 2002-10-07 2004-04-15 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
CN102245605A (zh) * 2008-10-14 2011-11-16 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018233663A1 (zh) * 2017-06-22 2018-12-27 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN109111465A (zh) * 2017-06-22 2019-01-01 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11180509B2 (en) 2017-06-22 2021-11-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Thiazolidone spiro pyrimidine trione compound, preparation method therefor and uses thereof

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
TWI657818B (zh) 2019-05-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
EA033459B1 (ru) 2019-10-31
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
MX365261B (es) 2019-05-27
PH12016502271B1 (en) 2017-02-06
KR20170007818A (ko) 2017-01-20
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
AU2015265620B2 (en) 2020-04-09
SG11201609404SA (en) 2016-12-29
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Spížek et al. Lincomycin, clindamycin and their applications
Slinger et al. Multiple combination antibiotic susceptibility testing of nontypeable Haemophilus influenzae biofilms
US10039777B2 (en) Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
JP7490696B2 (ja) 抗生物質感受性の全同定のためのアッセイ
Kc et al. Bacteriological study of wound infection and antibiotic susceptibility pattern of the isolates
CN108658991B (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
CN106659725A (zh) 用于治疗细菌感染的稠合螺环杂芳族化合物
Sharp et al. Amikacin (BB-K8) treatment of multiple-drug-resistant Proteus infections
Yamaguchi et al. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002
Okee et al. Prevalence of virulence determinants in Staphylococcus epidermidis from ICU patients in Kampala, Uganda
Stein et al. Newer oral antimicrobials for resistant respiratory tract pathogens: which show the most promise?
Al-Mayahie et al. Prevalence and Antimicrobial Susceptibility of Methicillin-Resistant Staphylococcus aureus (MRSA) from Outpatients with Chronic Rhinosinusitis in Al-Kut/Wasit Province/Iraq
Almayali Lastname.; Al-Kraety, IAA; Naji, AM and Abd almunaam, LH Bacteriological study and its antibiotics susceptibility pattern of Otitis Media in Iraqi patients
Rouev et al. Analysis of nasal and pharyngeal microbiological isolates collected in 2023 in Hospital Trakia–Stara Zagora
US20070281992A1 (en) Combination of gyrase b inhibitors and protein synthesis inhibitors and uses thereof
Ijabani et al. Antibiogram and Plasmid Mediated Resistance in Bacteria Isolated from Infected Wounds
Nsofor et al. High antibiotic resistance pattern observed in bacterial isolates from a tertiary Hospital in South East Nigeria
Zhandos SPECIFIC COMPOSITION OF MICROFLORA IN PURULENT SURGICAL INFECTION AND THEIR ANTIBIOTIC SENSITIVITY
Kulaste et al. Prevalence of microorganisms causing mastitis in dairy animals and their antibiotic resistance
Khan et al. Prevalence of multidrug resistant Staphylococcus aureus isolates in clinical specimens collected from local patients of Chittagong, Bangladesh
Olaiya A Study on Antibiotic Susceptibility Pattern of DNase Positive Staphylococci Isolated from Selected Libraries of Halls of Residence in Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria
SARITHA STUDIES ON ANTIMICROBIAL RESISTANCE (AMR) IN PREDOMINANT STAPHYLOCOCCI AND Escherichia coli ASSOCIATED WITH BOVINE MASTITIS AND COMBINATORIAL APPROACH FOR MITIGATION OF AMR
Bagde et al. Study of antibiotic susceptibility test of modern generation of drugs against upper respiratory tract pathogens
Sodani et al. Study of the antibiotic sensitivity pattern of Pseudomonas aeruginosa and its mechanism of resistance
Husain et al. An evaluation of the resistance pattern of different clinical isolates of bacteria against Cephradine and Cefotaxime

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: British diesel

Applicant after: ASTRAZENECA AB

Address before: London, England

Applicant before: ASTRAZENECA AB

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510